C9095 – Inj, tebentafusp-tebn, 1 mcg

Long description

Inj, tebentafusp-tebn, 1 mcg

Short description

Inj, tebentafusp-tebn, 1 mcg

Pricing indicator

53 Statute

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

O1D Chemotherapy

Added

July 1, 2022

Last change

October 1, 2022 – No change

Termination date

September 30, 2022

Nearby C codes

• C9087 – Injection, cyclophosphamide, (auromedics), 10 mg
• C9088 – Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
• C9089 – Bupivacaine, collagen-matrix implant, 1 mg
• C9090 – Injection, plasminogen, human-tvmh, 1 mg
• C9091 – Injection, sirolimus protein-bound particles, 1 mg
• C9092 – Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg
• C9093 – Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg
• C9094 – Inj, sutimlimab-jome, 10 mg
• C9096 – Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
• C9097 – Inj, faricimab-svoa, 0.1 mg
• C9098 – Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
• C9101 – Injection, oliceridine, 0.1 mg
• C9113 – Injection, pantoprazole sodium, per vial
• C9121 – Injection, argatroban, per 5 mg
• C9122 – Mometasone furoate sinus implant, 10 micrograms (sinuva)
• C9132 – Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity